Flu Season is On the Way!

It is that time of year again; flu season is upon us. The American Gastroenterological Association, the Crohn’s and Colitis Foundation of America, and the Centers for Medicare and Medicaid Services have all agreed that it is important for patients with inflammatory bowel disease to get flu shots every year.

Giving patients the flu vaccine is considered a requirement for high-quality care of IBD patients, so we are required to order the flu shot for every IBD patient. We would like to get everyone vaccinated before December 1st, and hopefully keep everyone out of the intensive care unit this year. Important things you should know about the flu shot:

- The flu vaccine covers more than one strain of flu
- If you have an egg allergy, there is a new egg-free vaccine called FluBlok
- If you choose to refuse the flu shot, we must document this in your medical record
- If you have had the flu shot somewhere else already, tell us when and where so that we can document this

Don’t forget about our upcoming Patient-2-Patient Education Event held in April, 2019!

Together the Michigan Crohn’s and Colitis Student Initiative and Michigan IBD Program will be holding a free informational event for IBD patients and their friends and families. Watch for more details and registration information

There has been significant growth of the IBD clinic at Metro Heath, University of Michigan in Grand Rapids. The Crohn’s and Colitis Foundation will be honoring Dr. Jami Kinnucan and the Metro Health team for all they are doing for IBD patients.

Upcoming Events:
- Sep. 29, 2018
  County Farm Park, Ann Arbor
- Oct. 6, 2018
  Toledo Zoo, Toledo

For more information or to take part in these events, please visit: crohnscolitisfoundation.org
ABT494—Upadacitinib
*Oral tablet (Recruitment on hold until Aug. 2018)*
This is a phase 2b/3 study for patients with moderate to severe Ulcerative Colitis to evaluate the safety and effectiveness of a new medication targeting JAK1.

Figaro—SHP647
*Subcutaneous injection*
This is a phase 3 study to evaluate the safety and efficacy of SHP647 in patients with moderate to severe Ulcerative Colitis. If eligible you will go through a 12 week induction, 52 week maintenance and a long term open label until the drug is approved by the FDA.

**Observational**

**Sparc:** Identify new tests to predict who will respond to what treatment

**Target:** 5 year study for adults and pediatrics to specifically address clinical questions that remain unanswered from registration trials

**Biofire:** To determine if intestinal infections are associated with flares of irritable bowel syndrome with diarrhea

**Databank:** Collect various samples from healthy volunteers and those with IBD

**PASS:** To learn more about long-term use and safety of Vedolizumab used in IBD treatment

Bergamont—etrolizumab
*Subcutaneous Injection*
This is a phase three study for patients with moderate to severely active Crohn’s disease to evaluate the safety and effectiveness of etrolizumab, which targets anti-integrin b7.

M16-006—Risakinumab
*IV Induction / Subcutaneous injections for maintenance*
This is a phase 3 study to evaluate the safety and efficacy of Risakinumab in subjects with moderate to severe Crohns Disease.

Dine CD
*Dietary*
This study is to compare the effectiveness of a specific carbohydrate diet and Mediterranean style diet to induce symptoms and clinical remission in patients with active Crohns disease.

ABT494—Upadacitinib
*Oral tablet*
This is a phase 3 study to evaluate the safety and efficacy of Upadacitinib in subjects with moderate to severe Crohns Disease. If eligible, subjects could be in the study for up to 244 weeks.